Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amphastar PharmaceuticalsAMPH -1.84%84 3-Year EBITDA Growth Rate is 16.50% as of Mar. 2026, which is 16% below its 10-year median of 19.60. GuruFocus rates AMPH with a GF Score™ of 84/100 and a GF Value™ of $49.08 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 813 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 62.85% on this metric.
During the past 12 months, Amphastar Pharmaceuticals's average EBITDA Per Share Growth Rate was -19.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 44.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 46.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amphastar Pharmaceuticals was 148.00% per year. The lowest was -73.80% per year. And the median was 19.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Amphastar Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
AMPH vs ESPR, NIKA, BIOA: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.50% mean?
Amphastar Pharmaceuticals (AMPH) has a 3-Year EBITDA Growth Rate of 16.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amphastar Pharmaceuticals and its competitors. This is 16% below median its historical median of 19.60. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #302 out of 813 companies in the Drug Manufacturers industry, placing it in the top 37.1%.
Is Amphastar Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Amphastar Pharmaceuticals' current 3-Year EBITDA Growth Rate of 16.50% is 16% below median its 10-year median of 19.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Amphastar Pharmaceuticals' value of 16.50% is 87.5% above this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #302 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amphastar Pharmaceuticals has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ESPR and NIKA?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #302 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Amphastar Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Amphastar Pharmaceuticals' value of 16.50% is 87.5% above this benchmark. While the company's 10-year median is 19.60 vs. the industry median of 8.80, Amphastar Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current 3-Year EBITDA Growth Rate of 16.50% is 87.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current 3-Year EBITDA Growth Rate is 16.50%, which is 16% below median its own 10-year median of 19.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $49.08, compared to a current price of $20.23 — trading 58.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.50%, which is 16% below median its 10-year median of 19.60 and 87.5% above the Drug Manufacturers industry median of 8.80. Amphastar Pharmaceuticals' overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current 3-Year EBITDA Growth Rate is 16.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.23 is trading 58.8% below its estimated GF Value™ of $49.08.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
3-Year EBITDA Growth Rate: 16.50% (16% below median its 10-year median of 19.60)
GF Value™: $49.08 vs. price of $20.23 (58.8% below fair value)
Industry Position: 87.5% above the Drug Manufacturers median (#302 of 813)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
84GF Score
Get the complete analysis for AMPH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
